Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody

Journal of Immunology

Volumn 183, Issue 9, 2009, Pages 5748-5755

  Hu, Jian ^a   Huang, Xiaodong ^a   Ling, Chang Chun ^b   Bundle, David R ^c   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GANGLIOSIDE GD3; GANGLIOSIDE GM2; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BASE SEQUENCE; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CARBOHYDRATE SEQUENCE; CLONE CELLS; CROSS REACTIONS; GANGLIOSIDES; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGOSACCHARIDES; PEPTIDE LIBRARY; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED;

EID: 77953063005     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901409     Document Type: Article

References (30)

1. Zuckier, L. S., E. Z. Berkowitz, R. J. Sattenberg, Q. H. Zhao, H. F. Deng, and M. D. Scharff. 2000. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res. 60: 7008-7013.
2. Batista, F. D., and M. S. Neuberger. 1998. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8: 751-759.
3. Rathanaswami, P., S. Roalstad, L. Roskos, Q. J. Su, S. Lackie, and J. Babcook. 2005. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem. Biophys. Res. Commun. 334: 1004-1013.
4. Steidl, S., O. Ratsch, B. Brocks, M. Durr, and E. Thomassen-Wolf. 2008. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol. Immunol. 46: 135-144.
5. Carsetti, R., G. Kohler, and M. C. Lamers. 1995. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181: 2129-2140.
6. Strasser, A., H. Puthalakath, L. A. O'Reilly, and P. Bouillet. 2008. What do we know about the mechanisms of elimination of autoreactive T and B cells and what challenges remain. Immunol. Cell Biol. 86: 57-66.
7. Nossal, G. J. 1994. Negative selection of lymphocytes. Cell 76: 229-239.
8. Palmer, E. 2003. Negative selection- clearing out the bad apples from the T-cell repertoire. Nat. Rev. 3: 383-391.
9. Vanderlugt, C. L., and S. D. Miller. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. 2: 85-95.
10. Deshmukh, U. S., H. Bagavant, J. Lewis, F. Gaskin, and S. M. Fu. 2005. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin. Immunol. 117: 112-120.
11. Svennerholm, L. 1964. The gangliosides. J. Lipid Res. 5: 145-155.
12. Modak, S., and N. K. Cheung. 2007. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 25: 67-77.
13. Kushner, B., K. Kramer, S. Modak, and N. K. Cheung. 2007. Anti-GD2 anitbody 3F8 plus granulocyte-macrophage colony stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in the bone marrow (BM). Proc. Amer. Soc. Clin. Oncol. 25: 526s (Abstr.).
14. Yu, A. L., A. L. Gilman, M. F. Ozkaynak, W. B. London, S. Kreissman, H. X. Chen, K. K. Matthay, S. L. Cohn, J. M. Maris, and P. Sondel. 2009. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J Clin Oncol. 27(Suppl. 15s): 10067z (Abstr.).
15. Modak, S, and N. K. Cheung. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat. Rev. In press.
16. Cheung, N. K., S. Modak, Y. Lin, H. Guo, P. Zanzonico, J. Chung, Y. Zuo, J. Sanderson, S. Wilbert, L. J. Theodore, D. B. Axworthy, and S. M. Larson. 2004. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J. Nucl. Med. 45: 867-877.
17. Yu, R. K., E. Bieberich, T. Xia, and G. Zeng. 2004. Regulation of ganglioside biosynthesis in the nervous system. J. Lipid Res. 45: 783-793.
18. Willison, H. J., K. Townson, J. Veitch, J. Boffey, N. Isaacs, S. M. Andersen, P. Zhang, C. C. Ling, and D. R. Bundle. 2004. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127: 680-691.
19. Andersen, S. M., C. C. Ling, P. Zhang, K. Townson, H. J. Willison, and D. R. Bundle. 2004. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barre syndrome. Org. Biomol. Chem. 2: 1199-1212.
20. Saito, M., R. K. Yu, and N. K. Cheung. 1985. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem. Biophys. Res. Commun. 127: 1-7.
21. Schultz, J., Y. Lin, J. Sanderson, Y. Zuo, D. Stone, R. Mallett, S. Wilbert, and D. Axworthy. 2000. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60: 6663-6669.
22. Catimel, B., A. M. Scott, F. T. Lee, N. Hanai, G. Ritter, S. Welt, L. J. Old, A. W. Burgess, and E. C. Nice. 1998. Direct immobilization of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization. Glycobiology 8: 927-938.
23. Li, Z., C. J. Woo, M. D. Iglesias-Ussel, D. Ronai, and M. D. Scharff. 2004. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 18: 1-11.
24. Rogozin, I. B., and M. Diaz. 2004. Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. J. Immunol. 172: 3382-3384.
25. Handgretinger, R., P. Baader, R. Dopfer, T. Klingebiel, P. Reuland, J. Treuner, R. A. Reisfeld, and D. Niethammer. 1992. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother. 35: 199-204.
26. Yu, A. L., S. D. Gillies, and R. A. Reisfeld. 1991. Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma. Proc. Am. Soc. Clin. Oncol. 10: 318.
27. Cheung, N. K., H. Lazarus, F. D. Miraldi, C. R. Abramowsky, S. Kallick, U. M. Saarinen, T. Spitzer, S. E. Strandjord, P. F. Coccia, and N. A. Berger. 1987. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5: 1430-1440.
28. Gong, Y., Y. Tagawa, M. P. Lunn, W. Laroy, M. Heffer-Lauc, C. Y. Li, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh. 2002. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 125: 2491-2506.
29. Goodnow, C. C., J. Sprent, B. Fazekas de St Groth, and C. G. Vinuesa. 2005. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435: 590-597.
30. Manjarrez-Orduno, N., T. D. Quach, and I. Sanz. 2009. B cells and immunological tolerance. J. Invest. Dermatol. 129: 278-288.